Table 1.
Characteristics of patients with discrepancies between HbA1c and FPG
| HbA1c ≥ 6.5% and FPG < 7.0 mmol/L (n = 1761) |
HbA1c < 6.5% and FPG ≥ 7.0 mmol/L (n = 511) |
P value | |
|---|---|---|---|
| Age (years, mean [SD]) | 65.4(11.2) | 65.4(10.9) | 0.947 |
| Male (n [%]) | 1184(67.2) | 348(68.1) | 0.713 |
| Systolic blood pressure (mmHg, mean [SD]) | 135.0(22.8) | 135.0(25.2) | 0.895 |
| Diastolic blood pressure (mmHg, median [IQR]) | 78.0(70.0, 87.0) | 78.0(70.0, 89.0) | 0.442 |
| Heart rate (bpm. Median [IQR]) | 78.0(68.0, 87.0) | 80.0(70.0, 90.0) | < 0.001 |
| Current smoker (n [%]) | 508(28.8) | 153(29.9) | 0.047 |
| Family history of CHD (n [%]) | 71(4.0) | 21(4.1) | 0.937 |
| Hypertension (n [%]) | 1300(73.8) | 403(78.9) | 0.021 |
| Previous acute myocardial infarction (n [%]) | 214(12.2) | 58(11.4) | 0.623 |
| Previous coronary artery bypass grafting (n [%]) | 16(0.9) | 4(0.8) | 0.789 |
| Atrial fibrillation history (n [%]) | 53(3.0) | 14(2.7) | 0.751 |
| Heart failure history (n [%]) | 58(3.3) | 19(3.7) | 0.640 |
| Cerebrovascular disease history (n [%]) | 185(10.5) | 57(11.2) | 0.675 |
| Peripheral artery disease history (n [%]) | 31(1.8) | 10(2.0) | 0.769 |
| Killip class (n [%]) | 0.289 | ||
| I or II | 1505(85.5) | 427(83.6) | |
| III or IV | 256(14.5) | 84(16.4) | |
| Types of ACS (n [%]) | < 0.001 | ||
| STEMI | 716(40.7) | 276(54.0) | |
| NSTE-ACS | 1045(59.3) | 235(46.0) | |
| HbA1c (%, mean [SD]) | 8.2(14.7) | 5.8(0.8) | < 0.001 |
| FPG (mmol/L, mean [SD])/(mg/dl, mean [SD]) | 5.6(1.2)/100.8(21.6) | 9.5(2.6)/171.0(46.8) | < 0.001 |
| eGFR (ml min−1 [1.73 m]−2, mean [SD]) | 79.1(25.1) | 76.4(27.3) | 0.046 |
| Hemoglobin (g/l, mean [SD]) | 132.1(20.4) | 132.4(23.6) | 0.192 |
| Total cholesterol (mmol/L, median [IQR])/(mg/dl, median [IQR]) | 4.3(3.5, 5.1)/166.2(135.3, 197.2) | 4.3(3.5, 5.1)/166.2(135.3, 197.2) | 0.721 |
| HDL-cholesterol (mmol/L, median [IQR])/(mg/dl, median [IQR]) | 1.0(0.8, 1.2)/38.7(30.9, 46.4) | 1.0(0.8, 1.2)/38.7(30.9, 46.4) | 0.931 |
| LDL-cholesterol (mmol/L, median [IQR])/(mg/dl, median [IQR]) | 2.6(2.0, 3.2)/100.5(77.3, 123.7) | 2.5(2.0, 3.2)/96.7(77.3, 123.7) | 0.326 |
| Triglyceride (mmol/L, median [IQR])/(mg/dl, median [IQR]) | 1.6(1.1, 2.4)/141.8(97.5, 212.6) | 1.5(1.0, 2.3)/132.9(88.6, 203.8) | 0.027 |
| Oral glucose-lowering agents or insulin use before admission (n [%]) | 809(45.9) | 288(56.4) | < 0.001 |
| Therapy during hospitalization (n [%]) | |||
| Percutaneous coronary intervention | 1170(66.4) | 337(65.9) | 0.836 |
| Aspirin | 1644(93.4) | 482(94.3) | 0.432 |
| P2Y12 inhibitors | 1603(91.0) | 473(92.6) | 0.276 |
| Statins | 1653(93.9) | 477(93.3) | 0.669 |
| β-blockers | 1146(65.1) | 291(56.9) | 0.001 |
| ACE inhibitor/angiotensin receptor blocker | 917(52.1) | 248(48.5) | 0.159 |
| Patients with referral (n [%]) | 587(33.3) | 172(33.7) | 0.891 |
ACE Angiotensin-converting enzyme, ACS Acute coronary syndrome, CHD Coronary heart disease, eGFR Estimated glomerular filtration rate, FPG Fasting plasma glucose, HbA1c Glycosylated hemoglobin, HDL High-density lipoprotein, IQR Interquartile range, LDL Low-density lipoprotein, NSTE-ACS Non-ST-segment elevation acute coronary syndrome, SD Standard deviation, STEMI ST-segment elevation myocardial infarction